{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:57:25Z","timestamp":1790870245988,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bvth.2026.100206","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:38:43Z","timestamp":1787848723000},"page":"100206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of anti\u2013factor Xa in patients with cancer receiving prophylactic low-molecular-weight heparin: a meta-analysis"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6200-2001","authenticated-orcid":false,"given":"Jeffrey","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6208-7488","authenticated-orcid":false,"given":"Timothy","family":"Nold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8437-6800","authenticated-orcid":false,"given":"Andrew","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7997-2835","authenticated-orcid":false,"given":"Charity","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bvth.2026.100206_bib1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.bvth.2026.100206_bib2","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bvth.2026.100206_bib3","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.bvth.2026.100206_bib4","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy","volume":"3","author":"Al-Samkari","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.bvth.2026.100206_bib5","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood.2024025362","article-title":"Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study","volume":"144","author":"Englisch","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bvth.2026.100206_bib6","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2015.5844","article-title":"The anti-factor Xa range for low molecular weight heparin thromboprophylaxis","volume":"7","author":"Wei","year":"2015","journal-title":"Hematol Rep"},{"issue":"8","key":"10.1016\/j.bvth.2026.100206_bib8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jamasurg.2019.1165","article-title":"Assessment of anti\u2013factor Xa levels of patients undergoing colorectal surgery given once-daily enoxaparin prophylaxis: a clinical study examining enoxaparin pharmacokinetics","volume":"154","author":"Pannucci","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.bvth.2026.100206_bib9","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bvth.2026.100206_bib11","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.bvth.2026.100206_bib12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1055\/s-0042-1749340","article-title":"Standard fixed enoxaparin dosing for venous thromboembolism prophylaxis leads to low peak anti-factor Xa levels in both head and neck and breast free flap patients","volume":"38","author":"Ambani","year":"2022","journal-title":"J Reconstr Microsurg"},{"key":"10.1016\/j.bvth.2026.100206_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jss.2017.08.053","article-title":"Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery","volume":"221","author":"Baumgartner","year":"2018","journal-title":"J Surg Res"},{"issue":"3","key":"10.1016\/j.bvth.2026.100206_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jamcollsurg.2019.11.012","article-title":"Prophylactic enoxaparin adjusted by anti-factor Xa peak levels compared with recommended thromboprophylaxis and rates of clinically evident venous thromboembolism in surgical oncology patients","volume":"230","author":"Kramme","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.bvth.2026.100206_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/00031348211023438","article-title":"Safety and efficacy of prophylactic enoxaparin adjusted by anti-factor Xa peak levels in pancreatic surgery","volume":"89","author":"Kramme","year":"2023","journal-title":"Am Surg"},{"issue":"6","key":"10.1016\/j.bvth.2026.100206_bib16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.amjsurg.2022.12.001","article-title":"Rate of prophylactic anti-Xa achievement and impact on venous thromboembolism following oncologic hepato-pancreatico-biliary surgery: a prospective cohort study","volume":"225","author":"Verhoeff","year":"2023","journal-title":"Am J Surg"},{"issue":"4","key":"10.1016\/j.bvth.2026.100206_bib17","first-page":"2919","article-title":"Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis","volume":"30","author":"Frere","year":"2022","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.bvth.2026.100206_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11239-009-0418-z","article-title":"Using low molecular weight heparin in special patient populations","volume":"29","author":"Lim","year":"2010","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.bvth.2026.100206_bib19","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1345\/aph.1L194","article-title":"Anticoagulation: low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings","volume":"43","author":"Nutescu","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"16","key":"10.1016\/j.bvth.2026.100206_bib20","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/eurheartj\/ehaf453","article-title":"Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis","volume":"47","author":"Khan","year":"2026","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.bvth.2026.100206_bib21","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/S2352-3026(25)00291-1","article-title":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial","volume":"13","author":"Mah\u00e9","year":"2026","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.bvth.2026.100206_bib22","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bvth.2026.100206_bib23","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jcpt.13169","article-title":"The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: a systematic review and meta-analysis","volume":"45","author":"Wu","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.bvth.2026.100206_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.6004\/jnccn.2021.7112","article-title":"Optimizing thromboembolism prophylaxis for the contemporary age of multiple myeloma","volume":"20","author":"Baljevic","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.bvth.2026.100206_bib25","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/jth.15354","article-title":"Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy","volume":"19","author":"Watson","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.bvth.2026.100206_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061169","article-title":"Challenges and advances in managing thrombocytopenic cancer patients","volume":"10","author":"Leader","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.bvth.2026.100206_bib27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1160\/TH13-04-0352","article-title":"Platelet count and outcome in patients with acute venous thromboembolism","volume":"110","author":"Di Micco","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bvth.2026.100206_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103186","article-title":"Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: a network meta-analysis","volume":"157","author":"Das","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.bvth.2026.100206_bib29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","article-title":"Cancer-associated venous thromboembolic disease, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Streiff","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"24","key":"10.1016\/j.bvth.2026.100206_bib30","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1161\/CIR.0000000000000769","article-title":"Call to action to prevent venous thromboembolism in hospitalized patients: a policy statement from the American Heart Association","volume":"141","author":"Henke","year":"2020","journal-title":"Circulation"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:21:06Z","timestamp":1790868066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950327226000719"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100206","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of anti\u2013factor Xa in patients with cancer receiving prophylactic low-molecular-weight heparin: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100206"}}